CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8 enrolled
Drug / intervention
Acipimoxdrug
Likely dose
Acipimox 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02796950
NCT02796950N/ACompleted
CompareCT.gov

The Effect of Acipimox on GLP-1 Secretion in Healthy Subjects: a Pilot Study

University of Aarhus·interventional·Posted Jun 13, 2016·Updated May 8, 2018

In Brief

A clinical study evaluating Acipimox for Diabetes Mellitus Type 2. Completed, enrolled 8 participants across 1 site.

Detailed Summary

Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus). Recently it was found, that levels of GLP-1 are increased in response to acipimox. The hypothesis is that G protein coupled receptors on enteroendocrine L cells bind acipimox and thereby induce GLP-1 secretion. In a controlled, open, randomized experiment, eight healthy, overweight men will be studied on an intervention day, where they receive acipimox, and on a control day. The study day includes an OGTT (oral glucose tolerance test), blood samples before and after the OGTT and a biopsy from adipose tissue.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus Type 2
CountriesDenmark
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 13, 2016
Enrollment StartJun 1, 2016
Primary CompletionJan 20, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.1 years ago

Interventions

Acipimoxdrug

P.o. administration of 250 mg acipimox